Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor

Hinrichs, 2014, Exploiting the curative potential of adoptive T-cell therapy for cancer, Immunol Rev, 257, 56, 10.1111/imr.12132 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat Med, 14, 1264, 10.1038/nm.1882 Straathof, 2005, Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes, Blood, 105, 1898, 10.1182/blood-2004-07-2975 Bollard, 2007, Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer, Blood, 110, 2838, 10.1182/blood-2007-05-091280 Bollard, 2014, Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins, J Clin Oncol, 32, 798, 10.1200/JCO.2013.51.5304 Chia, 2014, Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma, Mol Ther, 22, 132, 10.1038/mt.2013.242 Leen, 2007, Improving T cell therapy for cancer, Annu Rev Immunol, 25, 243, 10.1146/annurev.immunol.25.022106.141527 Peggs, 2009, Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists, Clin Exp Immunol, 157, 9, 10.1111/j.1365-2249.2009.03912.x Rabinovich, 2007, Immunosuppressive strategies that are mediated by tumor cells, Annu Rev Immunol, 25, 267, 10.1146/annurev.immunol.25.022106.141609 Callahan, 2013, At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy, J Leukoc Biol, 94, 41, 10.1189/jlb.1212631 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133 Bollard, 2002, Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity, Blood, 99, 3179, 10.1182/blood.V99.9.3179 Lacuesta, 2006, Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor, J Immunother, 29, 250, 10.1097/01.cji.0000192104.24583.ca Pangault, 2010, Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis, Leukemia, 24, 2080, 10.1038/leu.2010.223 Conticello, 2004, IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins, J Immunol, 172, 5467, 10.4049/jimmunol.172.9.5467 Roca, 2012, IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation, J Cell Biochem, 113, 1569 Todaro, 2007, Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4, Cell Stem Cell, 1, 389, 10.1016/j.stem.2007.08.001 Todaro, 2008, Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4, Cell Death Differ, 15, 762, 10.1038/sj.cdd.4402305 Wurster, 2000, The biology of Stat4 and Stat6, Oncogene, 19, 2577, 10.1038/sj.onc.1203485 Faffe, 2006, Interleukin-13 and interleukin-4 induce vascular endothelial growth factor release from airway smooth muscle cells: role of vascular endothelial growth factor genotype, Am J Respir Cell Mol Biol, 34, 213, 10.1165/rcmb.2005-0147OC Nelms, 1999, The IL-4 receptor: signaling mechanisms and biologic functions, Annu Rev Immunol, 17, 701, 10.1146/annurev.immunol.17.1.701 Jiang, 2004, Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members, Mol Cell Biol, 24, 6501, 10.1128/MCB.24.14.6501-6513.2004 Barata, 2001, Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1), Blood, 98, 1524, 10.1182/blood.V98.5.1524 Palmada, 2006, SGK1 kinase upregulates GLUT1 activity and plasma membrane expression, Diabetes, 55, 421, 10.2337/diabetes.55.02.06.db05-0720 Wolchok, 2010, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, Lancet Oncol, 11, 155, 10.1016/S1470-2045(09)70334-1 Wolchok, 2013, Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials, Ann Oncol, 24, 2174, 10.1093/annonc/mdt161 Denton, 2001, Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis, Curr Opin Rheumatol, 13, 505, 10.1097/00002281-200111000-00010 Overwijk, 2009, Functions of γC cytokines in immune homeostasis: current and potential clinical applications, Clin Immunol, 132, 153, 10.1016/j.clim.2009.03.512 Walsh, 2012, Structural insights into the common γ-chain family of cytokines and receptors from the interleukin-7 pathway, Immunol Rev, 250, 303, 10.1111/j.1600-065X.2012.01160.x Morrow, 1992, Interleukin-7 induces N-myc and c-myc expression in normal precursor B lymphocytes, Genes Dev, 6, 61, 10.1101/gad.6.1.61 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol Ther, 18, 843, 10.1038/mt.2010.24 Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity, Mol Ther, 21, 904, 10.1038/mt.2013.17 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964 Wilkie, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J Clin Immunol, 32, 1059, 10.1007/s10875-012-9689-9 Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat Biotechnol, 31, 71, 10.1038/nbt.2459 Anurathapan, 2014, Kinetics of tumor destruction by chimeric antigen receptor-modified T cells, Mol Ther, 22, 623, 10.1038/mt.2013.262 Hacein-Bey-Abina, 2003, A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency, N Engl J Med, 348, 255, 10.1056/NEJM200301163480314 Hacein-Bey-Abina, 2003, LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, 302, 415, 10.1126/science.1088547 Bear, 2012, Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?, Mol Ther, 20, 246, 10.1038/mt.2011.288 Scholler, 2012, Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells, Sci Transl Med, 4, 132ra53, 10.1126/scitranslmed.3003761 Rooney, 1995, Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation, Lancet, 345, 9, 10.1016/S0140-6736(95)91150-2 Vera, 2010, Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex), J Immunother, 33, 305, 10.1097/CJI.0b013e3181c0c3cb Vera, 2009, Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7, Mol Ther, 17, 880, 10.1038/mt.2009.34 Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data, Biostatistics, 4, 249, 10.1093/biostatistics/4.2.249